我們已在上線! 進一步了解
SURF

Surface Oncology, Inc. Common Stock

已下市

SURF已於2023年9月7日下市。

 

關於: Surface Oncology Inc is a clinical-stage immuno-oncology company. It is developing new therapies that modify the spaces in and around tumors in the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. The company's pipeline products are SRF231, SRF373, SRF617, and SRF388. Geographically, the activities are carried out throughout the region of the United States.

員工: 35

新聞

正面
中性
負面
市場情緒 3個月
正面 0%
中性 0%
負面 0%

我們尚未收到任何關於SURF的最新新聞文章。

價格圖表採用Lightweight Charts™實作